Literature DB >> 25557557

Evaluation of Treatments for Pruritus in Epidermolysis Bullosa.

Christina Danial1, Rasidat Adeduntan1, Emily S Gorell1, Anne W Lucky2, Amy S Paller3,4, Anna L Bruckner5,6, Elena Pope7, Kimberly D Morel8,9, Moise L Levy10, Shufeng Li1, Elaine S Gilmore11, Alfred T Lane1.   

Abstract

Pruritus is a common complication in patients with epidermolysis bullosa (EB). There is limited published data about the treatments that individuals with EB use for pruritus. The objective of the current study was to determine quantitatively which treatments individuals with EB have used for pruritus and to evaluate the perceived effectiveness of these treatments in pruritus relief. A questionnaire was developed to evaluate the treatments and therapies used for pruritus in patients of all ages and for all types of EB. Questions about bathing products, moisturizers, topical products, oral medications, dressings, and alternative therapies were included. A 5-point Likert scale (-2 = relieves itch a lot, -1 = relieves itch a little, 0 = no change, 1 = increases itch a little, 2 = increases itch a lot) was used to evaluate perceived effectiveness. Patients from seven North American EB centers were invited to participate. Greasy ointments (53.4%), lotions (45.2%), creams (40.4%), and oral hydroxyzine (39.0%) were the most frequently used treatments for pruritus. Treatments that were used frequently and perceived to be the most effective included creams (mean = -1.1), topical prescription corticosteroids (mean = -1.0), oils (mean = -0.9), oral hydroxyzine (mean = -0.9), topical diphenhydramine (mean = -0.9), and vaporizing rub (menthol, camphor, eucalyptus) (mean = -0.9). Systemic opioids (mean = 0.3), adherent bandages (mean = 0.3), and bleach baths (mean = 0.2) slightly increased pruritus. Randomized controlled trials of therapies will be necessary to develop evidence-based recommendations for control of pruritus in individuals with EB.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25557557      PMCID: PMC5079440          DOI: 10.1111/pde.12486

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  20 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Concomitant allergic contact dermatitis from diphenhydramine and metronidazole.

Authors:  Beatriz Fernández-Jorge; Jaime Goday Buján; Rosa Fernández-Torres; Romina Rodríguez-Lojo; Eduardo Fonseca
Journal:  Contact Dermatitis       Date:  2008-08       Impact factor: 6.600

Review 3.  Pain management in epidermolysis bullosa.

Authors:  Kenneth R Goldschneider; Anne W Lucky
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

4.  High genetic diversity of Staphylococcus aureus strains colonizing patients with epidermolysis bullosa.

Authors:  Magdalena M van der Kooi-Pol; Yanka K Veenstra-Kyuchukova; José C Duipmans; Gerlinde N Pluister; Leo M Schouls; Albert J de Neeling; Hajo Grundmann; Marcel F Jonkman; Jan Maarten van Dijl
Journal:  Exp Dermatol       Date:  2012-06       Impact factor: 3.960

5.  Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms.

Authors:  Ian M Paul; Jessica S Beiler; Tonya S King; Edelveis R Clapp; Julie Vallati; Cheston M Berlin
Journal:  Pediatrics       Date:  2010-11-08       Impact factor: 7.124

6.  Prevalence and characterization of pruritus in epidermolysis bullosa.

Authors:  Christina Danial; Rasidat Adeduntan; Emily S Gorell; Anne W Lucky; Amy S Paller; Anna Bruckner; Elena Pope; Kimberly D Morel; Moise L Levy; Shufeng Li; Elaine S Gilmore; Alfred T Lane
Journal:  Pediatr Dermatol       Date:  2014-09-18       Impact factor: 1.588

Review 7.  The role of nasal carriage in Staphylococcus aureus infections.

Authors:  Heiman F L Wertheim; Damian C Melles; Margreet C Vos; Willem van Leeuwen; Alex van Belkum; Henri A Verbrugh; Jan L Nouwen
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

8.  Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

Authors:  Jennifer T Huang; Melissa Abrams; Brook Tlougan; Alfred Rademaker; Amy S Paller
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

9.  Hand function and quality of life in children with epidermolysis bullosa.

Authors:  Emily A Eismann; Anne W Lucky; Roger Cornwall
Journal:  Pediatr Dermatol       Date:  2013-11-26       Impact factor: 1.588

10.  Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis.

Authors:  Caitriona Ryan; Richard E Shaw; Clay J Cockerell; Shari Hand; Fred E Ghali
Journal:  Pediatr Dermatol       Date:  2013 May-Jun       Impact factor: 1.588

View more
  2 in total

1.  Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.

Authors:  Rocío Maseda; Lucía Martínez-Santamaría; Rosa Sacedón; Nora Butta; María Del Carmen de Arriba; Sara García-Barcenilla; Marta García; Nuria Illera; Isabel Pérez-Conde; Marta Carretero; Eva Jiménez; Gustavo Melen; Alberto M Borobia; Víctor Jiménez-Yuste; Ángeles Vicente; Marcela Del Río; Raúl de Lucas; María José Escámez
Journal:  Front Med (Lausanne)       Date:  2020-11-26

2.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.